Dr. John Cush RheumNow
1 year 1 month ago
China study of 670 SpA pts rx w/ sulfasalazine betw 2016 to 2023 (469 pure AS; 201 w/ peripheral Sxs). SSZ Signif. reduced peripheral Sxs development (HR 0.49) and improved disease activity in both pure axial and axial-with-peripheral Sxs. https://t.co/5HdQCos9yM https://t.co/tTMScQDHBq
Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.
Dr. John Cush RheumNow
1 year 1 month ago
My Cancelled Lecture Slides
Dr. Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture.
https://t.co/uqj0J6Ii3e https://t.co/ePLc3xnCsF
Dr. John Cush RheumNow
1 year 1 month ago
Physical Therapy Underprescribed
Just one patient in six was referred for physical therapy (PT) within 15 days of being treated for knee pain at one major U.S. health system, researchers found, despite nearly universal consensus that PT should be recommended in most https://t.co/WM4NA6p2Pg
Dr. John Cush RheumNow
1 year 1 month ago
Prenatal acetaminophen linked to increased autism and ADHD
Researchers at the Icahn School of Medicine at Mount Sinai have found that prenatal exposure to acetaminophen may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and ADHD, in https://t.co/Zpo9dymPPf
Dr. John Cush RheumNow
1 year 1 month ago
Antibiotics are not linked to Autoimmune disease in kids
The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, https://t.co/46Q0GFZQiw
The American College of Rheumatology (ACR) is calling on Alaska and Montana to seize the opportunity to address critical gaps in rheumatology care by accessing funding from the Rural Health Transformation Program (RHTP), provided by the One Big Beautiful Bill Act (H.R. 1), signed into law on July 4, 2025.
Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal laboratory finding occur early in therapy (first 6 months) or are anticipated or only after dose escalation.
Dr. John Cush RheumNow
1 year 1 month ago
"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead
You are thoughtful, and committed. You will change this world! https://t.co/OFGN223bPa
Dr. John Cush RheumNow
1 year 1 month ago
While the live-attenuated vaccine, Ixchiq, was pulled for safety concerns, there is another chikungunya vax still on the marked - a virus-like particle vaccine, Vimkunya. Travelers or the elderly at higher risk of chikungunya exposure should consider getting vaccinated
Dr. John Cush RheumNow
1 year 1 month ago
👩⚕️🧑⚕️ RheumIQ is here.
Each week, challenge yourself with 5 quick questions on the latest in rheumatology.
✅ Fast
✅ Evidence-based
✅ Competitive
➡️ Test your RheumIQ today: https://t.co/OjhbnTjFyZ https://t.co/JrPfPn3N8n
Dr. John Cush RheumNow
1 year 1 month ago
MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/QdUzra1fnj
Dr. John Cush RheumNow
1 year 1 month ago
September is Rheumatic Disease Awareness Month! ARP president Adam Goode, Encourages Physical Activity During September - exercise, move, & get strong!! https://t.co/HhdnJdvBjR https://t.co/BuqTAMJaqN
